{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:59:19Z","timestamp":1790495959639,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.autrev.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,2,14]],"date-time":"2016-02-14T07:18:04Z","timestamp":1455434284000},"page":"544-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Biotherapies in large vessel vasculitis"],"prefix":"10.1016","volume":"15","author":[{"given":"Y.","family":"Ferfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Comarmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Messas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Savey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.02.012_bb0005","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1161\/CIRCULATIONAHA.107.760686","article-title":"Aortitis","volume":"117","author":"Gornik","year":"2008","journal-title":"Circulation"},{"issue":"Suppl. 64","key":"10.1016\/j.autrev.2016.02.012_bb0010","first-page":"92","article-title":"The pathology of large-vessel vasculitides","volume":"29","author":"Miller","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/0003-4819-104-1-74","article-title":"Relapsing polychondritis: survival and predictive role of early disease manifestations","volume":"104","author":"Michet","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2016.02.012_bb0020","first-page":"96","article-title":"Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients","volume":"24","author":"Zeuner","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-003-0400-6","article-title":"Cytokine inhibitors: soluble tumor necrosis factors receptor 1 and interleukin-1 receptor antagonist in Behcet's disease","volume":"25","author":"Duzgun","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2016.02.012_bb0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cyto.2003.09.003","article-title":"Cytokine production profile in patients with Behcet's disease treated with infliximab","volume":"24","author":"Misumi","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2016.02.012_bb0035","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/art.10815","article-title":"Mulcahy- Haves K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphism?","volume":"48","author":"Ahmad","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.012_bb0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.humimm.2006.12.006","article-title":"Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease","volume":"68","author":"Kamoun","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.autrev.2011.08.001","article-title":"Pathogenesis of Takayasu's arteritis: a 2011 update","volume":"11","author":"Arnaud","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.02.012_bb0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.02.012_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.012_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0889-857X(21)00371-9","article-title":"Treatment of resistant Takayasu's arteritis","volume":"21","author":"Hoffman","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2016.02.012_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.02.012_bb0070","first-page":"205","article-title":"Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy","volume":"5","author":"Salvarani","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1986.tb02796.x","article-title":"Long-term corticosteroid treatment in giant cell arteritis","volume":"220","author":"Andersson","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.autrev.2016.02.012_bb0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.012_bb0085","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoff man","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.012_bb0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jbspin.2011.11.008","article-title":"Efficacy of tocilizumab in refractory giant cell arteritis","volume":"79","author":"Vinit","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.012_bb0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.012_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.revmed.2012.12.012","article-title":"Efficacit\u00e9 Clinique et biologique du tocilizumab au cours de la maladie de Horton: \u00e0 propos de trois observations et revue de la litt\u00e9rature","volume":"35","author":"Kieffer","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2016.02.012_bb0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2016.02.012_bb0110","first-page":"2p","author":"Lurati","year":"2012","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0115","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","article-title":"Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2016.02.012_bb0120","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s00296-012-2516-z","article-title":"Tocilizumab for giant cell arteritis: an amazing result","volume":"33","author":"I\u015f\u0131k","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2016.02.012_bb0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10067-012-2007-3","article-title":"Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab","volume":"31","author":"Besada","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2011.4135","article-title":"Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement","author":"Christidis","year":"2011","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2016.02.012_bb0135","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3899\/jrheum.110496","article-title":"Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis","volume":"38","author":"Sciascia","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0140","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2016.02.012_bb0145","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"Suppl. 82","key":"10.1016\/j.autrev.2016.02.012_bb0150","first-page":"76","article-title":"Tocilizumab, an effective treatment for relapsing giant cell arteritis","volume":"32,3","author":"Oliveira","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 82","key":"10.1016\/j.autrev.2016.02.012_bb0155","first-page":"79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0160","doi-asserted-by":"crossref","unstructured":"Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, et Stone JH. Design of the tocilizumab in giant cell arteritis trial Int J Rheum 2013; (10pp.) doi:http:\/\/dx.doi.org\/10.1155\/2013\/912562.","DOI":"10.1155\/2013\/912562"},{"key":"10.1016\/j.autrev.2016.02.012_bb0165","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Carre\u00f1o L, L\u00f3pez-Longo J, Figueroa M, Belzunegui J, Mola EM, et Bonilla G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67, 5: 625\u201330. doi:http:\/\/dx.doi.org\/10.1136\/ard.2007.082115.","DOI":"10.1136\/ard.2007.082115"},{"issue":"12","key":"10.1016\/j.autrev.2016.02.012_bb0170","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2016.02.012_bb0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.012_bb0180","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.51.7.904","article-title":"Induction of remission in a patient with Takayasu's arteritis by low dose pulses of methotrexate","volume":"51","author":"Mevorach","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2016.02.012_bb0185","first-page":"1793","article-title":"Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis","volume":"30","author":"Valsakumar","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.012_bb0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/0003-4819-103-1-121","article-title":"Takayasu's arteritis and its therapy","volume":"103","author":"Shelhamer","year":"1985","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.autrev.2016.02.012_bb0195","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","article-title":"Anti-TNF-\u03b1 in refractory Takayasu's arteritis: cases series and review of the literature","volume":"11","author":"Comarmond","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2016.02.012_bb0200","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","article-title":"Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study","volume":"51","author":"Mekinian","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.012_bb0205","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/acr.21636","article-title":"Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow up","volume":"64","author":"Schmidt","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.012_bb0210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jpeds.2008.04.049","article-title":"Treatment of Takayasu's arteritis with tumor necrosis factor antagonists","volume":"153","author":"Filocamo","year":"2008","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.012_bb0215","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2016.02.012_bb0220","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.012_bb0225","first-page":"304","article-title":"Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. International angiology","volume":"24","author":"Tat\u00f2","year":"2005","journal-title":"J Int Union Angiol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00296-009-1147-5","article-title":"Infliximab therapy in pediatric Takayasu's arteritis: report of two cases","volume":"31","author":"Buonuomo","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2016.02.012_bb0235","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keh661","article-title":"Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?","volume":"44","author":"Della Rossa","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2016.02.012_bb0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","article-title":"Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate","volume":"45","author":"Tanaka","year":"2006","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.012_bb0245","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10067-006-0227-0","article-title":"Infliximab in Takayasu arteritis: a safe alternative?","volume":"26","author":"Karageorgaki","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0250","first-page":"63","article-title":"Refractory Takayasu arteritis successfully treated with infliximab","volume":"13","author":"Maffei","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.autrev.2016.02.012_bb0255","first-page":"145","article-title":"Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis","volume":"102","author":"Calder\u00f3n","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.autrev.2016.02.012_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket107","article-title":"Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis","author":"Xenitidis","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2016.02.012_bb0265","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.012_bb0270","first-page":"1","article-title":"Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-\u03b1 blockers","volume":"30","author":"Salvarani","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.012_bb0275","first-page":"98","article-title":"One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab","volume":"30","author":"Bredemeier","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2016.02.012_bb0280","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.autrev.2013.06.019","article-title":"Et club rhumatismes et inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review","volume":"12","author":"Abisror","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"18","key":"10.1016\/j.autrev.2016.02.012_bb0285","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.114.014321","article-title":"Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients","volume":"132","author":"Mekinian","year":"2015","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.autrev.2016.02.012_bb0290","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.012_bb0295","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.autrev.2014.01.056","article-title":"Biotherapies in Beh\u00e7et's disease","volume":"13","author":"Comarmond","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2016.02.012_bb0300","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","article-title":"Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment","volume":"65","author":"Baki","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.012_bb0305","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","article-title":"Infliximab in the treatment of hepatic vein thrombosis (Budd\u2013Chiari syndrome) in three patients with Behcet's syndrome","volume":"46","author":"Seyahi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.012_bb0310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.012_bb0315","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2011.02.006","article-title":"Resolution of Beh\u00e7et's syndrome associated pulmonary arterial aneurysms with infliximab","volume":"41","author":"Schreiber","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl. 67","key":"10.1016\/j.autrev.2016.02.012_bb0320","first-page":"S94","article-title":"Infliximab for life-threatening pulmonary artery aneurysms in Behcet's disease: a case report","volume":"29,4","author":"Tolosa-Vilella","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.012_bb0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Behcet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.012_bb0330","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00296-013-2693-4","article-title":"SN. Heyman. Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Beh\u00e7et's disease","volume":"34","author":"Aamar","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2016.02.012_bb0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.012_bb0340","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.autrev.2013.07.005","article-title":"Pathogenesis of relapsing polychondritis: a 2013 update","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2016.02.012_bb0345","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.autrev.2010.02.016","article-title":"Relapsing polychondritis: an autoimmune disease with many faces","volume":"9","author":"Lahmer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.02.012_bb0350","doi-asserted-by":"crossref","unstructured":"Vitale A, Sota J, Rigante D, Lopalco G, Molinaro F, Messina M, Lannone F, et Cantarini L. Relapsing polychondritis: an update on pathogenesis, clinical features, diagnostic tools, and therapeutic perspectives. Curr Rheumatol Rep 2016; 18, 1: 3. [doi:10.1007\/s11926\u2013015-0549-5].","DOI":"10.1007\/s11926-015-0549-5"},{"issue":"11","key":"10.1016\/j.autrev.2016.02.012_bb0355","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/rheumatology\/kem229","article-title":"Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis","volume":"46","author":"Seymour","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2016.02.012_bb0360","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/rheumatology\/kep224","article-title":"Sustained response to infliximab in a patient with relapsing polychondritis with aortic involvement","volume":"48","author":"Marie","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.012_bb0365","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00296-009-1308-6","article-title":"Treatment of relapsing polychondritis in the era of biological agents","volume":"30","author":"McCarthy","year":"2010","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.012_bb0370","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10067-014-2670-7","article-title":"Sustained response to tocilizumab in a patient with relapsing polychondritis with aortic involvement: a case based review","volume":"34","author":"Stael","year":"2015","journal-title":"Clin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:02:59Z","timestamp":1752577379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216300386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1568997216300386"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotherapies in large vessel vasculitis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}